Antibodies target microvessels in neuromyelitis optica and multiple sclerosis patients

References

• de Seze J, Lebrun C, Stojkovic T, Ferriby D, Chatel M, Vermersch P. Is Devic's neuromyelitis optica a separate disease? A comparative study with multiple sclerosis. Mult Scler. 2003;9(5):521–5.
   PubMed Web of Science ®Google Scholar
• Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology. 1999;53(5):1107–14.
   PubMed Web of Science ®Google Scholar
• Cheng Q, Miao L, Zhang J, Guan YT, Liu ZG, Wang X, et al.. Clinical features of patients with multiple sclerosis from a survey in Shanghai, China. Mult Scler. 2008;14(5):671–8.
   PubMed Web of Science ®Google Scholar
• Mealy MA, Wingerchuk DM, Greenberg BM, Levy M. Epidemiology of neuromyelitis optica in the United States: a multicenter analysis. Arch Neurol. 2012;69(9):1176–80.
   PubMedGoogle Scholar
• Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, et al.. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004;364(9451):2106–12.
   PubMed Web of Science ®Google Scholar
• Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med. 2005;202(4):473–7.
   PubMed Web of Science ®Google Scholar
• Jarius S, Franciotta D, Paul F, Ruprecht K, Bergamaschi R, Rommer PS, et al.. Cerebrospinal fluid antibodies to aquaporin-4 in neuromyelitis optica and related disorders: frequency, origin, and diagnostic relevance. J Neuroinflammation. 2010;7:52.
   PubMed Web of Science ®Google Scholar
• De Vidi I, Boursier G, Delouche N, Portalès P, Cadars E, Bouthier M, et al.. Strategy for anti-aquaporin-4 auto-antibody identification and quantification using a new cell-based assay. Clin Immunol. 2011;138(3):239–46.
   PubMed Web of Science ®Google Scholar
• Long Y, Qiu W, Lu Z, Bao J, Wu A, Wang Y, et al.. Aquaporin 4 antibodies in the cerebrospinal fluid are helpful in diagnosing Chinese patients with neuromyelitis optica. Neuroimmunomodulation. 2012;19(2):96–102.
   PubMed Web of Science ®Google Scholar
• Long Y, Hu X, Peng F, Wang Y, Yang Y, Qiu W, et al.. Neuromyelitis optica immunoglobulin G in Chinese patients detected by immunofluorescence assay on a monkey brain substrate. Neuroimmunomodulation. 2012;19(1):20–4.
   PubMed Web of Science ®Google Scholar
• Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006;66(10):1485–9.
   PubMed Web of Science ®Google Scholar
• Jarius S, Frederikson J, Waters P, Paul F, Akman-Demir G, Marignier R, et al.. Frequency and prognostic impact of antibodies to aquaporin-4 in patients with optic neuritis. J Neurol Sci. 2010;298(1–2):158–62.
   PubMed Web of Science ®Google Scholar
• Matiello M, Lennon VA, Jacob A, Pittock SJ, Lucchinetti CF, Wingerchuk DM, et al.. NMO–IgG predicts the outcome of recurrent optic neuritis. Neurology. 2008;70(23):2197–200.
   PubMed Web of Science ®Google Scholar
• Scott TF, Kassab SL, Pittock SJ. Neuromyelitis optica IgG status in acute partial transverse myelitis. Arch Neurol. 2006;63(10):1398–400.
   PubMedGoogle Scholar
• Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al.. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69(2):292–302.
   PubMed Web of Science ®Google Scholar
• Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33(11):1444–52.
   PubMed Web of Science ®Google Scholar
• Pittock SJ, Lennon VA, Krecke K, Wingerchuk DM, Lucchinetti CF, Weinshenker BG. Brain abnormalities in neuromyelitis optica. Arch Neurol. 2006;63(3):390–6.
   PubMedGoogle Scholar
• Kim W, Kim SH, Huh SY, Kim HJ. Brain abnormalities in neuromyelitis optica spectrum disorder. Mult Scler Int. 2012;2012:735486.
   PubMedGoogle Scholar
• Papeix C, Vidal JS, de Seze J, Pierrot-Deseilligny C, Tourbah A, Stankoff B, et al.. Immunosuppressive therapy is more effective than interferon in neuromyelitis optica. Mult Scler. 2007;13(2):256–9.
   PubMed Web of Science ®Google Scholar
• Barnett MH, Prineas JW, Buckland ME, Parratt JD, Pollard JD. Massive astrocyte destruction in neuromyelitis optica despite natalizumab therapy. Mult Scler. 2012;18(1):108–12.
   PubMed Web of Science ®Google Scholar
• Kleiter I, Hellwig K, Berthele A, Kümpfel T, Linker RA, Hartung HP, et al.. Failure of natalizumab to prevent relapses in neuromyelitis optica. Arch Neurol. 2012;69(2):239–45.
   PubMedGoogle Scholar
• Kim SH, Kim W, Li XF, Jung IJ, Kim HJ. Does interferon beta treatment exacerbate neuromyelitis optica spectrum disorder. Mult Scler. 2012;18(10):1480–3.
   PubMed Web of Science ®Google Scholar
• Min JH, Kim BJ, Lee KH. Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder. Mult Scler. 2012;18(1):113–5.
   PubMed Web of Science ®Google Scholar
• Jarius S, Ruprecht K, Wildemann B, Kuempfel T, Ringelstein M, Geis C, et al.. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients. J Neuroinflammation. 2012;9:14.
   PubMed Web of Science ®Google Scholar
• Jarius S, Paul F, Franciotta D, de Seze J, Münch C, Salvetti M, et al.. Neuromyelitis optica spectrum disorders in patients with myasthenia gravis: ten new aquaporin-4 antibody positive cases and a review of the literature. Mult Scler. 2012;18(8):1135–43.
   PubMed Web of Science ®Google Scholar
• Saikali P, Cayrol R, Vincent T. Anti-aquaporin-4 auto-antibodies orchestrate the pathogenesis in neuromyelitis optica. Autoimmun Rev. 2009;9(2):132–5.
   PubMed Web of Science ®Google Scholar
• Jarius S, Wildemann B. AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance. Nat Rev Neurol. 2010;6(7):383–92.
   PubMed Web of Science ®Google Scholar
• Shimizu F, Sano Y, Takahashi T, Haruki H, Saito K, Koga M, et al.. Sera from neuromyelitis optica patients disrupt the blood-brain barrier. J Neurol Neurosurg Psychiatry. 2012;83(3):288–97.
   PubMed Web of Science ®Google Scholar
• Kinoshita M, Nakatsuji Y. Where do AQP4 antibodies fit in the pathogenesis of NMO. Mult Scler Int. 2012;2012:862169.
   PubMedGoogle Scholar
• Ratelade J, Bennett JL, Verkman AS. Evidence against cellular internalization in vivo of NMO–IgG, aquaporin-4, and excitatory amino acid transporter 2 in neuromyelitis optica. J Biol Chem. 2011;286(52):45156–64.
   PubMed Web of Science ®Google Scholar
• Hamnik SE, Hacein-Bey L, Biller J, Gruener G, Jay W. Neuromyelitis optica (NMO) antibody positivity in patients with transverse myelitis and no visual manifestations. Semin Ophthalmol. 2008;23(3):191–200.
   PubMedGoogle Scholar
• Lucchinetti CF, Mandler RN, McGavern D, Bruck W, Gleich G, Ransohoff RM, et al.. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain. 2002;125(Pt 7):1450–61.
   PubMed Web of Science ®Google Scholar
• Pittock SJ, Lennon VA, de Seze J, Vermersch P, Homburger HA, Wingerchuk DM, et al.. Neuromyelitis optica and non organ-specific autoimmunity. Arch Neurol. 2008;65(1):78–83.
   PubMedGoogle Scholar
• Alves-Leon SV, Pimentel ML, Sant'Anna G, Malfetano FR, Estrada CD, Quirico-Santos T. Immune system markers of neuroinflammation in patients with clinical diagnose of neuromyelitis optica. Arq Neuropsiquiatr. 2008;66(3B):678–84.
   PubMed Web of Science ®Google Scholar
• Jarius S, Neumayer B, Wandinger KP, Hartmann M, Wildemann B. Anti-endothelial serum antibodies in a patient with Susac's syndrome. J Neurol Sci. 2009;285(1–2):259–61.
   PubMed Web of Science ®Google Scholar
• Magro CM, Poe JC, Lubow M, Susac JO. Susac syndrome: an organ-specific autoimmune endotheliopathy syndrome associated with anti-endothelial cell antibodies. Am J Clin Pathol. 2011;136(6):903–12.
   PubMed Web of Science ®Google Scholar
• Belizna C, Duijvestijn A, Hamidou M, Tervaert JW. Antiendothelial cell antibodies in vasculitis and connective tissue disease. Ann Rheum Dis. 2006;65(12):1545–50.
   PubMed Web of Science ®Google Scholar
• Tintore M, Fernandez AL, Rovira A, Martinez X, Direskeneli H, Khamashta M, et al.. Antibodies against endothelial cells in patients with multiple sclerosis. Acta Neurol Scand. 1996;93(6):416–20.
   PubMed Web of Science ®Google Scholar
• Kotaska K, Petrak B, Kukacka J, Kraus J, Prusa R. Anti-vimentin antibodies and neuron-specific enolase in children with neurofibromatosis type-1. Neuro Endocrinol Lett. 2007;28(6):761–4.
   PubMed Web of Science ®Google Scholar
• Bell DA, Thiem PA, Vaughan JH, Leddy JP. Studies with human leukocyte lysosomes. Evidence for antilysosome antibodies in lupus erythematosus and for the presence of lysosomal antigen in inflammatory diseases. J Clin Invest. 1975;55(2):256–68.
   PubMed Web of Science ®Google Scholar